placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes
Understanding these side effects is vital for weight loss seekers to make informed decisions about their treatment options
All content contained on or available through this site is for general information purposes only
For the consultation itself, youll typically bill: Telehealth parity laws in many states ensure telehealth visits are reimbursed equally to in-person: Medicare continues to reimburse telehealth mental health visits at office rates through at least 2025 (likely extended into 2026)
It also adds uncertainty without proving better long-term outcomes
For context, gastric bypass surgery typically produces 2535% weight loss over a comparable timeframe
